- 11Articles reviewed
- 3Areas of expertise
About Nisar
Nisar Mohammed is the founder and managing director of WinHyCare, which he built with co-founder Moqtar Mohammed. He brings pharmaceutical-industry experience to Winhycare Pharma, the company’s peptide API and contract-manufacturing division in Hyderabad, India.
Before founding WinHyCare he spent 28 years and 8 months at Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical manufacturers.
Areas of expertise
- Pharmaceutical manufacturing
- Peptide APIs
- GMP operations
Articles reviewed by Nisar
Winhycare Pharma · Peptide APIs
CDMO vs CMO vs CRDMO: what is the difference, and which one does a pharma buyer need?
What CMO, CDMO and CRDMO mean in pharma, how their scope differs, what GMP rules apply to every contract manufacturer, and which model a buyer needs.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Generic semaglutide: EU and US regulatory pathways, and what API makers must show
How generic semaglutide is filed in the EU and US: generic vs hybrid, 8+2+1 protection, ANDA vs 505(b)(2), synthetic vs recombinant API, API maker duties.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
How to qualify a peptide API supplier: a documentation and audit checklist for EU and US buyers
A documentation and audit checklist for qualifying a peptide API supplier for EU and US filings: written confirmation, DMF/ASMF, GMP audit, impurities and agreements.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Lyophilised peptide stability and storage: how long a peptide API lasts and how to keep it
How long a lyophilised peptide API lasts, what degrades it, which storage temperatures ICH Q1A(R2) defines, how stability is tested and how to ship it safely.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Peptide API impurities and specifications: thresholds, tests and what regulators expect in 2026
How peptide API impurities are classified and controlled: why ICH Q3A does not apply, Ph. Eur. 0.1/0.5/1.0% thresholds, FDA's 2026 peptide guidance and what a specification covers.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Peptide lyophilisation: a practical guide to freeze-drying peptide APIs
How peptide freeze-drying works: freezing, primary and secondary drying, Tg′ and collapse temperature, excipients, cycle development and vial and stopper choices.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
How to read a semaglutide API certificate of analysis (COA)
A test-by-test guide to a semaglutide API COA: identity, assay, purity, peptide content, water, acetate, residual solvents, endotoxin and the specs behind them.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Semaglutide patent expiry by country: dates, status and what it means for API buyers
When semaglutide's compound protection ends in India, China, Canada, Brazil, the US, EU, UK and Japan, with primary sources, and what it means for API buyers.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
Semaglutide vs tirzepatide vs liraglutide: how the three peptide APIs compare
How semaglutide, tirzepatide and liraglutide APIs differ: backbone, length, lipid chain, receptors, half-life basis, molecular weight, CAS and approval.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
SPPS vs LPPS vs hybrid: how peptide APIs are manufactured, and why the route matters to buyers
Solid-phase, liquid-phase and hybrid peptide synthesis compared for API buyers: chemistry, length limits, impurities, scale, solvent use and regulatory impact.
Kareem Ahmed Basha
Winhycare Pharma · Peptide APIs
What is a peptide API? API vs drug substance explained
A peptide API is the active ingredient of a peptide medicine. How ICH, FDA and EU law define API, drug substance and active substance, and where peptides fit.
Kareem Ahmed Basha